[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Patient-derived Xenograft (PDX) Models Market 2024 by Company, Regions, Type and Application, Forecast to 2030

January 2024 | 131 pages | ID: G12D187EDA18EN
GlobalInfoResearch

US$ 3,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
According to our (Global Info Research) latest study, the global Patient-derived Xenograft (PDX) Models market size was valued at USD 341.2 million in 2023 and is forecast to a readjusted size of USD 591.4 million by 2030 with a CAGR of 8.2% during review period.

Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.

The Global Info Research report includes an overview of the development of the Patient-derived Xenograft (PDX) Models industry chain, the market status of Preclinical Drug development (Mouse Model, Rat Model), Biomarker Analysis (Mouse Model, Rat Model), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Patient-derived Xenograft (PDX) Models.

Regionally, the report analyzes the Patient-derived Xenograft (PDX) Models markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Patient-derived Xenograft (PDX) Models market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Patient-derived Xenograft (PDX) Models market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Patient-derived Xenograft (PDX) Models industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Mouse Model, Rat Model).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Patient-derived Xenograft (PDX) Models market.

Regional Analysis: The report involves examining the Patient-derived Xenograft (PDX) Models market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Patient-derived Xenograft (PDX) Models market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Patient-derived Xenograft (PDX) Models:

Company Analysis: Report covers individual Patient-derived Xenograft (PDX) Models players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Patient-derived Xenograft (PDX) Models This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Preclinical Drug development, Biomarker Analysis).

Technology Analysis: Report covers specific technologies relevant to Patient-derived Xenograft (PDX) Models. It assesses the current state, advancements, and potential future developments in Patient-derived Xenograft (PDX) Models areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Patient-derived Xenograft (PDX) Models market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Patient-derived Xenograft (PDX) Models market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
  • Mouse Model
  • Rat Model
Market segment by Application
  • Preclinical Drug development
  • Biomarker Analysis
Market segment by players, this report covers
  • Crown Bioscience
  • Champions Oncology
  • Wuxi Apptec
  • The Jackson Laboratory
  • EPO Berlin-Buch
  • Oncodesign
  • Xentech
  • Envigo
  • Charles River Laboratories
  • Pharmatest Services
  • Urosphere
  • MEDICILON
  • Horizon Discovery
  • Shanghai Model Organisms Center
  • GemPharmatech
  • LIDE Biotech
Market segment by regions, regional analysis covers
  • North America (United States, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
  • South America (Brazil, Argentina and Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Patient-derived Xenograft (PDX) Models product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Patient-derived Xenograft (PDX) Models, with revenue, gross margin and global market share of Patient-derived Xenograft (PDX) Models from 2019 to 2024.

Chapter 3, the Patient-derived Xenograft (PDX) Models competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Patient-derived Xenograft (PDX) Models market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Patient-derived Xenograft (PDX) Models.

Chapter 13, to describe Patient-derived Xenograft (PDX) Models research findings and conclusion.
1 MARKET OVERVIEW

1.1 Product Overview and Scope of Patient-derived Xenograft (PDX) Models
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Patient-derived Xenograft (PDX) Models by Type
  1.3.1 Overview: Global Patient-derived Xenograft (PDX) Models Market Size by Type: 2019 Versus 2023 Versus 2030
  1.3.2 Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type in 2023
  1.3.3 Mouse Model
  1.3.4 Rat Model
1.4 Global Patient-derived Xenograft (PDX) Models Market by Application
  1.4.1 Overview: Global Patient-derived Xenograft (PDX) Models Market Size by Application: 2019 Versus 2023 Versus 2030
  1.4.2 Preclinical Drug development
  1.4.3 Biomarker Analysis
1.5 Global Patient-derived Xenograft (PDX) Models Market Size & Forecast
1.6 Global Patient-derived Xenograft (PDX) Models Market Size and Forecast by Region
  1.6.1 Global Patient-derived Xenograft (PDX) Models Market Size by Region: 2019 VS 2023 VS 2030
  1.6.2 Global Patient-derived Xenograft (PDX) Models Market Size by Region, (2019-2030)
  1.6.3 North America Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
  1.6.4 Europe Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
  1.6.5 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
  1.6.6 South America Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
  1.6.7 Middle East and Africa Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)

2 COMPANY PROFILES

2.1 Crown Bioscience
  2.1.1 Crown Bioscience Details
  2.1.2 Crown Bioscience Major Business
  2.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Product and Solutions
  2.1.4 Crown Bioscience Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.1.5 Crown Bioscience Recent Developments and Future Plans
2.2 Champions Oncology
  2.2.1 Champions Oncology Details
  2.2.2 Champions Oncology Major Business
  2.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Product and Solutions
  2.2.4 Champions Oncology Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.2.5 Champions Oncology Recent Developments and Future Plans
2.3 Wuxi Apptec
  2.3.1 Wuxi Apptec Details
  2.3.2 Wuxi Apptec Major Business
  2.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Product and Solutions
  2.3.4 Wuxi Apptec Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.3.5 Wuxi Apptec Recent Developments and Future Plans
2.4 The Jackson Laboratory
  2.4.1 The Jackson Laboratory Details
  2.4.2 The Jackson Laboratory Major Business
  2.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Product and Solutions
  2.4.4 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.4.5 The Jackson Laboratory Recent Developments and Future Plans
2.5 EPO Berlin-Buch
  2.5.1 EPO Berlin-Buch Details
  2.5.2 EPO Berlin-Buch Major Business
  2.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Product and Solutions
  2.5.4 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.5.5 EPO Berlin-Buch Recent Developments and Future Plans
2.6 Oncodesign
  2.6.1 Oncodesign Details
  2.6.2 Oncodesign Major Business
  2.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Product and Solutions
  2.6.4 Oncodesign Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.6.5 Oncodesign Recent Developments and Future Plans
2.7 Xentech
  2.7.1 Xentech Details
  2.7.2 Xentech Major Business
  2.7.3 Xentech Patient-derived Xenograft (PDX) Models Product and Solutions
  2.7.4 Xentech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.7.5 Xentech Recent Developments and Future Plans
2.8 Envigo
  2.8.1 Envigo Details
  2.8.2 Envigo Major Business
  2.8.3 Envigo Patient-derived Xenograft (PDX) Models Product and Solutions
  2.8.4 Envigo Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.8.5 Envigo Recent Developments and Future Plans
2.9 Charles River Laboratories
  2.9.1 Charles River Laboratories Details
  2.9.2 Charles River Laboratories Major Business
  2.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Product and Solutions
  2.9.4 Charles River Laboratories Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.9.5 Charles River Laboratories Recent Developments and Future Plans
2.10 Pharmatest Services
  2.10.1 Pharmatest Services Details
  2.10.2 Pharmatest Services Major Business
  2.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Product and Solutions
  2.10.4 Pharmatest Services Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.10.5 Pharmatest Services Recent Developments and Future Plans
2.11 Urosphere
  2.11.1 Urosphere Details
  2.11.2 Urosphere Major Business
  2.11.3 Urosphere Patient-derived Xenograft (PDX) Models Product and Solutions
  2.11.4 Urosphere Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.11.5 Urosphere Recent Developments and Future Plans
2.12 MEDICILON
  2.12.1 MEDICILON Details
  2.12.2 MEDICILON Major Business
  2.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Product and Solutions
  2.12.4 MEDICILON Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.12.5 MEDICILON Recent Developments and Future Plans
2.13 Horizon Discovery
  2.13.1 Horizon Discovery Details
  2.13.2 Horizon Discovery Major Business
  2.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Product and Solutions
  2.13.4 Horizon Discovery Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.13.5 Horizon Discovery Recent Developments and Future Plans
2.14 Shanghai Model Organisms Center
  2.14.1 Shanghai Model Organisms Center Details
  2.14.2 Shanghai Model Organisms Center Major Business
  2.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Product and Solutions
  2.14.4 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.14.5 Shanghai Model Organisms Center Recent Developments and Future Plans
2.15 GemPharmatech
  2.15.1 GemPharmatech Details
  2.15.2 GemPharmatech Major Business
  2.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Product and Solutions
  2.15.4 GemPharmatech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.15.5 GemPharmatech Recent Developments and Future Plans
2.16 LIDE Biotech
  2.16.1 LIDE Biotech Details
  2.16.2 LIDE Biotech Major Business
  2.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Product and Solutions
  2.16.4 LIDE Biotech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
  2.16.5 LIDE Biotech Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Patient-derived Xenograft (PDX) Models Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
  3.2.1 Market Share of Patient-derived Xenograft (PDX) Models by Company Revenue
  3.2.2 Top 3 Patient-derived Xenograft (PDX) Models Players Market Share in 2023
  3.2.3 Top 6 Patient-derived Xenograft (PDX) Models Players Market Share in 2023
3.3 Patient-derived Xenograft (PDX) Models Market: Overall Company Footprint Analysis
  3.3.1 Patient-derived Xenograft (PDX) Models Market: Region Footprint
  3.3.2 Patient-derived Xenograft (PDX) Models Market: Company Product Type Footprint
  3.3.3 Patient-derived Xenograft (PDX) Models Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Patient-derived Xenograft (PDX) Models Consumption Value and Market Share by Type (2019-2024)
4.2 Global Patient-derived Xenograft (PDX) Models Market Forecast by Type (2025-2030)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2019-2024)
5.2 Global Patient-derived Xenograft (PDX) Models Market Forecast by Application (2025-2030)

6 NORTH AMERICA

6.1 North America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
6.2 North America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Country
  6.3.1 North America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
  6.3.2 United States Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  6.3.3 Canada Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  6.3.4 Mexico Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

7 EUROPE

7.1 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
7.2 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Country
  7.3.1 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
  7.3.2 Germany Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  7.3.3 France Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  7.3.4 United Kingdom Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  7.3.5 Russia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  7.3.6 Italy Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

8 ASIA-PACIFIC

8.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region
  8.3.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Region (2019-2030)
  8.3.2 China Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  8.3.3 Japan Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  8.3.4 South Korea Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  8.3.5 India Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  8.3.6 Southeast Asia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  8.3.7 Australia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

9 SOUTH AMERICA

9.1 South America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
9.2 South America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
9.3 South America Patient-derived Xenograft (PDX) Models Market Size by Country
  9.3.1 South America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
  9.3.2 Brazil Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  9.3.3 Argentina Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country
  10.3.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
  10.3.2 Turkey Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  10.3.3 Saudi Arabia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
  10.3.4 UAE Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

11 MARKET DYNAMICS

11.1 Patient-derived Xenograft (PDX) Models Market Drivers
11.2 Patient-derived Xenograft (PDX) Models Market Restraints
11.3 Patient-derived Xenograft (PDX) Models Trends Analysis
11.4 Porters Five Forces Analysis
  11.4.1 Threat of New Entrants
  11.4.2 Bargaining Power of Suppliers
  11.4.3 Bargaining Power of Buyers
  11.4.4 Threat of Substitutes
  11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Patient-derived Xenograft (PDX) Models Industry Chain
12.2 Patient-derived Xenograft (PDX) Models Upstream Analysis
12.3 Patient-derived Xenograft (PDX) Models Midstream Analysis
12.4 Patient-derived Xenograft (PDX) Models Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

LIST OF TABLES

Table 1. Global Patient-derived Xenograft (PDX) Models Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Patient-derived Xenograft (PDX) Models Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Patient-derived Xenograft (PDX) Models Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Patient-derived Xenograft (PDX) Models Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Crown Bioscience Company Information, Head Office, and Major Competitors
Table 6. Crown Bioscience Major Business
Table 7. Crown Bioscience Patient-derived Xenograft (PDX) Models Product and Solutions
Table 8. Crown Bioscience Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Crown Bioscience Recent Developments and Future Plans
Table 10. Champions Oncology Company Information, Head Office, and Major Competitors
Table 11. Champions Oncology Major Business
Table 12. Champions Oncology Patient-derived Xenograft (PDX) Models Product and Solutions
Table 13. Champions Oncology Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Champions Oncology Recent Developments and Future Plans
Table 15. Wuxi Apptec Company Information, Head Office, and Major Competitors
Table 16. Wuxi Apptec Major Business
Table 17. Wuxi Apptec Patient-derived Xenograft (PDX) Models Product and Solutions
Table 18. Wuxi Apptec Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Wuxi Apptec Recent Developments and Future Plans
Table 20. The Jackson Laboratory Company Information, Head Office, and Major Competitors
Table 21. The Jackson Laboratory Major Business
Table 22. The Jackson Laboratory Patient-derived Xenograft (PDX) Models Product and Solutions
Table 23. The Jackson Laboratory Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. The Jackson Laboratory Recent Developments and Future Plans
Table 25. EPO Berlin-Buch Company Information, Head Office, and Major Competitors
Table 26. EPO Berlin-Buch Major Business
Table 27. EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Product and Solutions
Table 28. EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. EPO Berlin-Buch Recent Developments and Future Plans
Table 30. Oncodesign Company Information, Head Office, and Major Competitors
Table 31. Oncodesign Major Business
Table 32. Oncodesign Patient-derived Xenograft (PDX) Models Product and Solutions
Table 33. Oncodesign Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Oncodesign Recent Developments and Future Plans
Table 35. Xentech Company Information, Head Office, and Major Competitors
Table 36. Xentech Major Business
Table 37. Xentech Patient-derived Xenograft (PDX) Models Product and Solutions
Table 38. Xentech Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Xentech Recent Developments and Future Plans
Table 40. Envigo Company Information, Head Office, and Major Competitors
Table 41. Envigo Major Business
Table 42. Envigo Patient-derived Xenograft (PDX) Models Product and Solutions
Table 43. Envigo Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Envigo Recent Developments and Future Plans
Table 45. Charles River Laboratories Company Information, Head Office, and Major Competitors
Table 46. Charles River Laboratories Major Business
Table 47. Charles River Laboratories Patient-derived Xenograft (PDX) Models Product and Solutions
Table 48. Charles River Laboratories Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Charles River Laboratories Recent Developments and Future Plans
Table 50. Pharmatest Services Company Information, Head Office, and Major Competitors
Table 51. Pharmatest Services Major Business
Table 52. Pharmatest Services Patient-derived Xenograft (PDX) Models Product and Solutions
Table 53. Pharmatest Services Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Pharmatest Services Recent Developments and Future Plans
Table 55. Urosphere Company Information, Head Office, and Major Competitors
Table 56. Urosphere Major Business
Table 57. Urosphere Patient-derived Xenograft (PDX) Models Product and Solutions
Table 58. Urosphere Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Urosphere Recent Developments and Future Plans
Table 60. MEDICILON Company Information, Head Office, and Major Competitors
Table 61. MEDICILON Major Business
Table 62. MEDICILON Patient-derived Xenograft (PDX) Models Product and Solutions
Table 63. MEDICILON Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. MEDICILON Recent Developments and Future Plans
Table 65. Horizon Discovery Company Information, Head Office, and Major Competitors
Table 66. Horizon Discovery Major Business
Table 67. Horizon Discovery Patient-derived Xenograft (PDX) Models Product and Solutions
Table 68. Horizon Discovery Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 69. Horizon Discovery Recent Developments and Future Plans
Table 70. Shanghai Model Organisms Center Company Information, Head Office, and Major Competitors
Table 71. Shanghai Model Organisms Center Major Business
Table 72. Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Product and Solutions
Table 73. Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 74. Shanghai Model Organisms Center Recent Developments and Future Plans
Table 75. GemPharmatech Company Information, Head Office, and Major Competitors
Table 76. GemPharmatech Major Business
Table 77. GemPharmatech Patient-derived Xenograft (PDX) Models Product and Solutions
Table 78. GemPharmatech Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 79. GemPharmatech Recent Developments and Future Plans
Table 80. LIDE Biotech Company Information, Head Office, and Major Competitors
Table 81. LIDE Biotech Major Business
Table 82. LIDE Biotech Patient-derived Xenograft (PDX) Models Product and Solutions
Table 83. LIDE Biotech Patient-derived Xenograft (PDX) Models Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 84. LIDE Biotech Recent Developments and Future Plans
Table 85. Global Patient-derived Xenograft (PDX) Models Revenue (USD Million) by Players (2019-2024)
Table 86. Global Patient-derived Xenograft (PDX) Models Revenue Share by Players (2019-2024)
Table 87. Breakdown of Patient-derived Xenograft (PDX) Models by Company Type (Tier 1, Tier 2, and Tier 3)
Table 88. Market Position of Players in Patient-derived Xenograft (PDX) Models, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 89. Head Office of Key Patient-derived Xenograft (PDX) Models Players
Table 90. Patient-derived Xenograft (PDX) Models Market: Company Product Type Footprint
Table 91. Patient-derived Xenograft (PDX) Models Market: Company Product Application Footprint
Table 92. Patient-derived Xenograft (PDX) Models New Market Entrants and Barriers to Market Entry
Table 93. Patient-derived Xenograft (PDX) Models Mergers, Acquisition, Agreements, and Collaborations
Table 94. Global Patient-derived Xenograft (PDX) Models Consumption Value (USD Million) by Type (2019-2024)
Table 95. Global Patient-derived Xenograft (PDX) Models Consumption Value Share by Type (2019-2024)
Table 96. Global Patient-derived Xenograft (PDX) Models Consumption Value Forecast by Type (2025-2030)
Table 97. Global Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2024)
Table 98. Global Patient-derived Xenograft (PDX) Models Consumption Value Forecast by Application (2025-2030)
Table 99. North America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2024) & (USD Million)
Table 100. North America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2025-2030) & (USD Million)
Table 101. North America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2024) & (USD Million)
Table 102. North America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2025-2030) & (USD Million)
Table 103. North America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2024) & (USD Million)
Table 104. North America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2025-2030) & (USD Million)
Table 105. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2024) & (USD Million)
Table 106. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Type (2025-2030) & (USD Million)
Table 107. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2024) & (USD Million)
Table 108. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Application (2025-2030) & (USD Million)
Table 109. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2024) & (USD Million)
Table 110. Europe Patient-derived Xenograft (PDX) Models Consumption Value by Country (2025-2030) & (USD Million)
Table 111. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2024) & (USD Million)
Table 112. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Type (2025-2030) & (USD Million)
Table 113. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2024) & (USD Million)
Table 114. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Application (2025-2030) & (USD Million)
Table 115. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Region (2019-2024) & (USD Million)
Table 116. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Region (2025-2030) & (USD Million)
Table 117. South America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2024) & (USD Million)
Table 118. South America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2025-2030) & (USD Million)
Table 119. South America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2024) & (USD Million)
Table 120. South America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2025-2030) & (USD Million)
Table 121. South America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2024) & (USD Million)
Table 122. South America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2025-2030) & (USD Million)
Table 123. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2024) & (USD Million)
Table 124. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Type (2025-2030) & (USD Million)
Table 125. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2024) & (USD Million)
Table 126. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Application (2025-2030) & (USD Million)
Table 127. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2024) & (USD Million)
Table 128. Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Country (2025-2030) & (USD Million)
Table 129. Patient-derived Xenograft (PDX) Models Raw Material
Table 130. Key Suppliers of Patient-derived Xenograft (PDX) Models Raw Materials

LIST OF FIGURES

Figure 1. Patient-derived Xenograft (PDX) Models Picture
Figure 2. Global Patient-derived Xenograft (PDX) Models Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type in 2023
Figure 4. Mouse Model
Figure 5. Rat Model
Figure 6. Global Patient-derived Xenograft (PDX) Models Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application in 2023
Figure 8. Preclinical Drug development Picture
Figure 9. Biomarker Analysis Picture
Figure 10. Global Patient-derived Xenograft (PDX) Models Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global Patient-derived Xenograft (PDX) Models Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Market Patient-derived Xenograft (PDX) Models Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 13. Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Region (2019-2030)
Figure 14. Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Region in 2023
Figure 15. North America Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 16. Europe Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 17. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 18. South America Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 19. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 20. Global Patient-derived Xenograft (PDX) Models Revenue Share by Players in 2023
Figure 21. Patient-derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 22. Global Top 3 Players Patient-derived Xenograft (PDX) Models Market Share in 2023
Figure 23. Global Top 6 Players Patient-derived Xenograft (PDX) Models Market Share in 2023
Figure 24. Global Patient-derived Xenograft (PDX) Models Consumption Value Share by Type (2019-2024)
Figure 25. Global Patient-derived Xenograft (PDX) Models Market Share Forecast by Type (2025-2030)
Figure 26. Global Patient-derived Xenograft (PDX) Models Consumption Value Share by Application (2019-2024)
Figure 27. Global Patient-derived Xenograft (PDX) Models Market Share Forecast by Application (2025-2030)
Figure 28. North America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2019-2030)
Figure 29. North America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2019-2030)
Figure 30. North America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2019-2030)
Figure 31. United States Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 32. Canada Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 33. Mexico Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 34. Europe Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2019-2030)
Figure 35. Europe Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2019-2030)
Figure 36. Europe Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2019-2030)
Figure 37. Germany Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 38. France Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 39. United Kingdom Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 40. Russia Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 41. Italy Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 42. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2019-2030)
Figure 43. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2019-2030)
Figure 44. Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Region (2019-2030)
Figure 45. China Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 46. Japan Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 47. South Korea Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 48. India Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 49. Southeast Asia Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 50. Australia Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 51. South America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2019-2030)
Figure 52. South America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2019-2030)
Figure 53. South America Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2019-2030)
Figure 54. Brazil Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 55. Argentina Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 56. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type (2019-2030)
Figure 57. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2019-2030)
Figure 58. Middle East and Africa Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Country (2019-2030)
Figure 59. Turkey Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 60. Saudi Arabia Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 61. UAE Patient-derived Xenograft (PDX) Models Consumption Value (2019-2030) & (USD Million)
Figure 62. Patient-derived Xenograft (PDX) Models Market Drivers
Figure 63. Patient-derived Xenograft (PDX) Models Market Restraints
Figure 64. Patient-derived Xenograft (PDX) Models Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Patient-derived Xenograft (PDX) Models in 2023
Figure 67. Manufacturing Process Analysis of Patient-derived Xenograft (PDX) Models
Figure 68. Patient-derived Xenograft (PDX) Models Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source


More Publications